Boji Medical (300404) 2025 Annual Report and 2026 Q1 Earnings Commentary: Robust Growth in Clinical Business in 2025 with High Order Growth Laying Foundation for Future Expansion

Event: The company released its annual report for 2025 and the first quarter report for 2026. In 2025, the company achieved operating revenue of 869 million yuan, representing a year-on-year increase of 17.06%; net profit attributable to shareholders reached 30.4942 million yuan.

Everbright SecuritiesApr 29 19:02

Boji Pharmaceutical (300404.SZ) reported a net profit of 30.4942 million yuan in 2025, representing a year-on-year increase of 5.97%.

Gelonghui reported on April 25 that Boji Pharmaceutical (300404.SZ) released its 2025 annual report, showing the company achieved total revenue of 869 million yuan for the full year, representing a year-on-year increase of 17.06%; net profit attributable to shareholders amounted to 30.4942 million yuan, marking a year-on-year growth of 5.97%; while non-recurring net profit attributable to shareholders stood at 19.2044 million yuan, reflecting a year-on-year decline of 0.52%. The company proposed a dividend distribution plan of 0.13 yuan per 10 shares for all shareholders.

Gelonghui FinanceApr 25 13:16

Boji Pharmaceutical: Summary of the 2025 Annual Report

SZSIApr 25 00:00 · Announcements

Boji Pharmaceutical: 2025 Annual Report

SZSIApr 25 00:00 · Announcements

Boji Pharmaceutical: First Quarter Report for 2026

SZSIApr 25 00:00 · Announcements

Bogee Medical (300404.SZ): Q1 net profit attributable to shareholders reached RMB 16.4608 million, increasing by 322.01% year-on-year.

Gelonghui, April 24th: Boji Pharmaceutical (300404.SZ) released its Q1 2026 report. During the reporting period, the company achieved operating revenue of 220 million yuan, representing a year-on-year increase of 58.54%; net profit attributable to shareholders of the listed company was 16.4608 million yuan, increasing by 322.01% year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.7084 million yuan, surging by 707.37% year-on-year; basic earnings per share were 0.043 yuan.

Gelonghui FinanceApr 24 21:22